Robert Dreicer, MD

PRIMARY APPOINTMENT:

Professor, Medicine: Hematology and Oncology

CONTACT:

UVA – Hematology & Oncology
Po Box 800716
Charlottesville, VA 22908
Telephone: 434.924.1775
Fax: 434.243.6086
Email: rd7va@virginia.edu

EDUCATION AND TRAINING:

Clinical Fellowship, Hem-Onc, University of Wisconsin Medical School
MD, University of Texas Health Sciences Center
Residency, Internal Medicine, Indiana University Medical Center

RESEARCH INTERESTS:

Novel therapeutic approaches for urologic cancers, including prostate, urothelial, and kidney cancers.

RESEARCH SUMMARY:

Novel therapeutic approaches for urologic cancers, including prostate, urothelial, and kidney cancers.

SELECT PUBLICATIONS:

Dreicer R, Chemotherapy for advanced urothelial cancer: end of the beginning?, 2017; The Lancet. Oncology. 18(5) 567-569. PMID: 28389317
Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM, Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline., 2017; The Journal of urology. () . PMID: 28456635
Dreicer R, Editorial Comment., 2017; Urology. 102() 157-158. PMID: 28131435
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial., 2016; Lancet (London, England). 389(10064) 67-76. PMID: 27939400
Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, Tse K, Petruck J, Webb IJ, Bander NH, Nanus DM, Scher HI, Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody-drug conjugate MLN2704 in metastatic castration-resistant prostate cancer., 2016; Urologic oncology. 34(12) 530.e15-530.e21. PMID: 27765518 | PMCID: PMC5464417
Dreicer R, Immunomodulatory treatment in urothelial cancer., 2016; The Lancet. Oncology. 17(11) 1475-1477. PMID: 27733242
Dreicer R, Highlights in Genitourinary (Prostate) Cancer., 2016; JAMA oncology. 2(10) 1257-1258. PMID: 27541619
Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E, Response to post-axitinib treatment in patients with metastatic renal cell carcinoma., 2016; BMC cancer. 16() 254. PMID: 27026229 | PMCID: PMC4810513